BillionToOne stock just absorbed a brutal shock. Shares closed at about US$91.56 after earnings, down almost 39% from the prior US$149.97 close, even though the company stayed in the black. Q2 basic earnings per share landed at US$0.17 on revenue of US$109.45m.
For short term traders, the move is already in the rearview mirror. For anyone thinking in years rather than hours, the bigger story is that BillionToOne has only recently turned profitable and still carries a rich P/E multiple on trailing numbers. The rest of the earnings report explains why that matters.
Love that BillionToOne is staying profitable but uncomfortable with a rich P/E and a 39% single day share price drop. Take a look at our hand picked 77 resilient stocks with low risk scores if you want stocks with steadier risk profiles and stronger downside resilience.
Q2 2026 Earnings Summary
- Revenue, Q2 2026 vs. Q2 2025: US$109.45m vs. US$66.57m (very large increase year on year)
- Net Income, Q2 2026 vs. Q2 2025: US$8.05m profit vs. US$0.25m loss (shift to profit)
- Basic EPS, Q2 2026 vs. Q2 2025: US$0.17 vs. a loss of US$0.02 per share (move into positive earnings per share)
- Trailing Twelve Month Revenue, Q2 2026 vs. Q2 2025: US$397.41m vs. US$209.03m (very large increase over the year)
Prefer clean charts over pages of raw earnings tables and footnotes? See BillionToOne's full financial picture, including how the market is valuing the stock after this Q2 report, in our company report for BillionToOne.
BillionToOne bull case meets real operating traction
Bulls argue that BillionToOne is building a high growth, profitable diagnostics platform anchored in UNITY prenatal tests and the Northstar oncology suite. Q2 revenue of US$109.45m and a US$8.05m profit follow a Q1 swing into the black, so the claim that growth can coexist with profitability is holding for now. The prenatal narrative of broad UNITY adoption and improved reimbursement fits with prior commentary on expanded payer contracts and larger covered life pools. Oncology believers point to the peer reviewed Northstar Response data and the recent oncology CMO hire as concrete steps toward deeper clinical use. The latest quarter shows the company still funding that agenda while staying profitable, which supports the idea that internal investment has not yet broken the income statement.
Bear case on BillionToOne faces mixed confirmation
The bear story centers on rich expectations, reimbursement and oncology mix risk, plus the cost of heavier R&D and commercial spend. The 39% single day share price drop and multi week declines of 34% over 7 days and 22% over 30 days show how quickly sentiment can reset when expectations are high. Concerns that oncology growth could pressure margins are not settled, since segment level profitability is not broken out here. Fears about reimbursement reversals are also unproven so far, with earlier quarters citing expanded coverage rather than cuts. The clearest bear validation today is not collapsing earnings. It is how sharply the stock fell even as BillionToOne stayed profitable, which underlines how exposed the story is to any wobble in growth or perceived execution.
Review how quickly sentiment flipped on BillionToOne, and scan our independent risk analysis for BillionToOne which shows 1 important warning sign to see whether deeper structural vulnerabilities are emerging.Stay Ahead Of Your Next Move
If the sharp BillionToOne share price swing after earnings has your attention, register for free with Simply Wall St and add it to a Watchlist so you can track price against fair value and watch for an entry point that fits your plan. Once you are invested, keep the focus on what matters by using the Portfolio Command Center to cut through noise and get timely, decision ready alerts on your holdings. For a broader view, lean on the Community to see how other investors are interpreting the same news and numbers. That way you can surface potential catalysts or risks early and aim to stay a step ahead of the market.
Seeking Alternatives Beyond BillionToOne?
Fresh ideas move fast. While attention sits on BillionToOne, other stocks may be building breakout momentum or quietly dropping into better value under the radar for now. Act now.
- Spot companies already building momentum and still flying under most radars by scanning a curated set of 18 high quality undiscovered gems before the crowd catches on.
- Lock onto potential compounding machines with resilient cash flows and sturdy balance sheets by running through a focused list of solid balance sheet and fundamentals stocks (50 results) while it still reflects fresh conditions.
- Target income opportunities that aim to hold up when markets wobble by reviewing a hand picked pool of 8 dividend fortresses before yields get compressed.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com